Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Allarity Therapeutics, Inc. - Common stock (NQ: ALLR ) 0.4471 -0.0229 (-4.87%) Streaming Delayed Price Updated: 12:40 PM EDT, Jun 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Allarity Therapeutics, Inc. - Common stock < Previous 1 2 Next > Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement May 20, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances May 14, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock May 07, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics Inc. (NASDAQ: ALLR) Near the Top of Equities by Percentage Gain on 4/12 April 12, 2024 Via Investor Brand Network Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1 May 06, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer May 02, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement April 29, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1) April 17, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics Announces 1-for-20 Reverse Stock Split April 04, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer March 27, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1) March 25, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update March 08, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics to Present at Biomarkers 2024 February 28, 2024 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor December 12, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic December 05, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics to Present at Biomarkers Europe 2023 October 02, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics Gaining Momentum? Hits Multiple Milestones Including Positive Publications In PLOS One And At ASCO, Positive Early Data From An Ongoing Clinical Trial, And External Partnering For Its DRP(R) Technology September 14, 2023 Via ACCESSWIRE PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib August 30, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics July 31, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives July 24, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering July 06, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics Inc. (NASDAQ: ALLR) Leading the Way in Wednesday Trading Based on Percentage Gain July 05, 2023 Via Investor Brand Network Allarity Therapeutics (NASDAQ: ALLR) Reports Early Success in Phase 2 Trial for Breast Cancer Drug IXEMPRA® July 05, 2023 Allarity Therapeutics (NASDAQ: ALLR), a clinical-stage pharmaceutical company, recently announced preliminary results from its Phase 2 clinical trial assessing the Via Spotlight Growth Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients July 05, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics Announces Reverse Stock Split of Common Stock June 28, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split June 27, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders June 20, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting May 30, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire Allarity Therapeutics Accelerates Trial Enrollment To Bring FDA-Approved Breast Cancer Treatment To European Market - Interim Results Could Be Released In Second Half Of 2023 April 27, 2023 Via ACCESSWIRE Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering April 19, 2023 From Allarity Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
